I'm sorry. I was just simply going to add to that point that, as has been mentioned before, throughout this regime it tries to ensure that the drugs are not exported for commercial purposes.
So again, providing this kind of information as part of providing an obligation on the authorization holder to provide a copy of the agreement, when signed, to the patentee and to the importing countries, helps ensure that there is transparency, but also that there are measures in place to ensure the regime is not used for commercial purposes, which would be contrary to the objectives of the WTO decision.